KRAS mutational status analysis of peripheral blood isolated circulating tumor cells in metastatic colorectal patients

Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar

Allegra CJ, Jessup JM, Somerfield MR, et al: American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 27:2091–2096. 2009. View Article : Google Scholar

Jimeno A, Messersmith WA, Hirsch FR, Franklin WA and Eckhardt SG: KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol. 27:1130–1136. 2009. View Article : Google Scholar

Sartore-Bianchi A, Bencardino K, Cassingena A, et al: Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer. Cancer Treat Rev. 36(Suppl 3): S1–S5. 2010. View Article : Google Scholar

De Roock W, De Vriendt V, Normanno N, Ciardiello F and Tejpar S: KRAS, BRAF, PIK3CA, and PTEN mutations: Implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 12:594–603. 2011.PubMed/NCBI

Artale S, Sartore-Bianchi A, Veronese SM, et al: Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol. 26:4217–4219. 2008. View Article : Google Scholar : PubMed/NCBI

Kosakowska EA, Stec R, Charkiewicz R, Skoczek M and Chyczewski L: Molecular differences in the KRAS gene mutation between a primary tumor and related metastatic sites - case report and a literature review. Folia Histochem Cytobiol. 48:597–602. 2010.

Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH and Gabbert HE: Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res. 16:790–799. 2010. View Article : Google Scholar : PubMed/NCBI

Ashworth T: A case of cancer in which cells similar to those in the tumours were seen in blood after death. Aust Med J. 14:146–149. 1869.

Gerges N, Rak J and Jabado N: New technologies for the detection of circulating tumour cells. Br Med Bull. 94:49–64. 2010. View Article : Google Scholar : PubMed/NCBI

Alunni-Fabbroni M and Sandri MT: Circulating tumour cells in clinical practice: Methods of detection and possible characterization. Methods. 50:289–297. 2010. View Article : Google Scholar : PubMed/NCBI

Lustberg M, Jatana KR, Zborowski M and Chalmers JJ: Emerging technologies for CTC detection based on depletion of normal cells. Recent Results Cancer Res. 195:97–110. 2012. View Article : Google Scholar : PubMed/NCBI

Baas JM, Krens LL, Guchelaar HJ, Morreau H and Gelderblom H: Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: A review. Oncologist. 16:1239–1249. 2011. View Article : Google Scholar : PubMed/NCBI

Bossard C, Küry S, Jamet P, et al: Delineation of the infrequent mosaicism of KRAS mutational status in metastatic colorectal adenocarcinomas. J Clin Pathol. 65:466–469. 2012. View Article : Google Scholar : PubMed/NCBI

Bouchahda M, Karaboué A, Saffroy R, et al: Acquired KRAS mutations during progression of colorectal cancer metastases: Possible implications for therapy and prognosis. Cancer Chemother Pharmacol. 66:605–609. 2010. View Article : Google Scholar : PubMed/NCBI

Wicha MS and Hayes DF: Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J Clin Oncol. 29:1508–1511. 2011. View Article : Google Scholar : PubMed/NCBI